Study the effect of Empagliflozin in type 2 diabetic patients
- Conditions
- Condition 1: Diabetes. Condition 2: Heart disease.Type 2 diabetes mellitus with other specified complicationE11.69
- Registration Number
- IRCT20210710051833N1
- Lead Sponsor
- Zanjan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 200
Type 2 diabetic patients (treated with oral hypoglycemic drugs) with STEMI (typical chest pain lasting more than 30 minutes during the 12 hours prior to admission, with ST-segment elevation above 0.1 mV in both Lead or more on ECG) who will be admitted to Ayatollah Mousavi Hospital in Zanjan between August and October 1401
Diabetic patients with MI who have previously received prior treatment with metformin, sulfonylureas, or a combination of these two drugs.
Cardiogenic shock
Hypoglycemia
Diabetic ketoacidosis
History of coronary artery bypass surgery
Type 1 diabetes
Severe liver failure
Patients with advanced cancer
History of severe hypersensitivity to empagliflozin or its components
Severe renal failure (eGFR <30 mL / minute / 1.73 m2), end-stage renal disease (ESRD) or dialysis
Hypovolemia
Any inflammatory disease being treated
History of any cancer
Advanced heart failure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mortality associated with cardiovascular events. Timepoint: Hospitalization time and one month and three months later. Method of measurement: Monthly face-to-face visits, tests and echoes.
- Secondary Outcome Measures
Name Time Method